👋 Hey, let’s get into it. Novo Nordisk spent years battling Eli Lilly for obesity market dominance. This week, it found itself battling something far less predictable: cybercriminals.

After revealing a security breach last week, reports now suggest two separate hacking groups demanded ransoms of $25 million and $50 million. Novo reportedly refused both demands. The attackers claim they obtained clinical trial information, intellectual property and details on obesity pipeline programs including amycretin and CagriSema.

The incident is a reminder that in modern pharma, your biggest adversary isn't always another drug company. Sometimes it's a ransomware group with a dark web leak.

📅 Quick programming note: there will be no BioNucleus Briefing on Tuesday, June 23 while we're away on vacation. We’ll be back on Thursday, June 25.

🎷 Jazz and AbCellera Strike Antibody Deal Worth Up to $792M Per Program
Jazz Pharmaceuticals is doubling down on oncology through a new partnership with AbCellera that could generate up to $792 million in milestone payments for each program Jazz chooses to advance. The collaboration focuses on T-cell engaging multispecific antibodies for gastrointestinal cancers and other solid tumors. AbCellera will initially develop two programs, with a third expected within a year. Jazz gains exclusive opt-in rights while leveraging AbCellera's discovery engine and protein engineering platform. The deal includes $56 million upfront plus another $28 million when the third program begins.

🤖 Merck Signs AI Drug Discovery Deal Worth Up to $510M With Protillion
Merck is betting that better data can build better AI models. The pharma giant signed a collaboration with Protillion Biosciences worth up to $510 million in potential milestones centered around Protillion's protein mapping technology. The platform generates large-scale datasets designed to train protein-design AI systems and identify biologics with complex therapeutic properties. As AI increasingly moves from biotech buzzword to business strategy, companies are spending heavily on platforms that can generate the high-quality data these models require.

🧬 FDA Reverses Course and Opens Path for uniQure's Huntington's Gene Therapy
After years of regulatory uncertainty, uniQure says the FDA has agreed that three-year phase 1/2 data may support accelerated approval for AMT-130 in Huntington's disease. The agency also appears willing to move away from requiring a controversial sham surgery-controlled study. The decision marks a dramatic shift from earlier FDA feedback and sends the company toward a planned biologics license application later this year. If approved, AMT-130 would become the first genetic medicine for Huntington's disease. uniQure shares rallied roughly 78% on the news.

🇨🇦 Colorado Wins FDA Approval to Import Lower-Cost Drugs From Canada
Colorado has become the second state after Florida to receive FDA authorization for a drug importation program designed to lower prescription costs. The state estimates the initiative could save patients $46 million over three years through reduced premiums and out-of-pocket expenses. The challenge now becomes finding drug supply. Canada has repeatedly warned against exports that could threaten domestic inventories, while manufacturers have shown little enthusiasm for supporting importation efforts.

💻 100+ ChatGPT Prompts to Revolutionize Your Day
Discover how you can leverage ChatGPT to boost efficiency, streamline tasks, and stay ahead in your industry. Supercharge your productivity with HubSpot's comprehensive guide.

💊 Lilly Buys Non-Opioid Pain Startup 4E Therapeutics
The acquisition gives Lilly a pipeline of early-stage pain medicines targeting the MNK-eIF4E pathway without the addiction risks associated with opioids.

🤖 Altaris Acquires Simulations Plus for $375M
The healthcare private equity firm plans to combine the AI-driven drug development company with its existing molecular design software business.

💉 FDA Review Appears Favorable for Moderna's mRNA Flu Vaccine
Briefing documents released ahead of an advisory committee meeting suggest Moderna's influenza vaccine enters the discussion with positive momentum, despite earlier FDA concerns.

📉 Elicio Shares Crash 73% After Pancreatic Cancer Miss
Although ELI-002 failed its phase 2 primary endpoint, the company still plans to advance the immunotherapy into phase 3 testing.

🧠 Vedana Launches With $46M for Next-Gen Migraine Drugs
The startup is developing anti-PACAP therapies aimed at patients who fail to respond to existing CGRP-targeting migraine treatments.

🪓 Neumora Cuts 35% of Staff After Phase 3 Failure
The biotech is discontinuing its lead depression program after two late-stage studies missed both primary and secondary endpoints.

If it feels like a biotech acquisition gets announced every other day, that's because it basically does. And 95% of the time Lilly seems to be the buyer.

According to PwC, biopharma dealmaking topped $65 billion in the first quarter of 2026, making it the strongest quarter for M&A activity since 2020. Even more impressive, 16 separate biopharma deals worth at least $1 billion were announced in just three months.

The biggest driver is a problem every large pharmaceutical company can see coming. More than $300 billion in branded drug revenue faces patent expiration this decade, forcing companies to replenish pipelines before exclusivity disappears.

That's helping fuel a rush into obesity, immunology, oncology, rare disease, radiopharmaceuticals, RNA medicines and gene editing. The focus isn't simply buying companies. It's buying differentiated science that can generate future revenue.

Interestingly, uncertainty around drug pricing reforms, tariffs and regulatory policy hasn't slowed dealmaking. Instead, buyers are getting more creative. Milestone-heavy deals, contingent value rights and performance-based payouts are becoming increasingly common.

Private equity firms are also entering the mix more aggressively, competing with traditional pharma buyers for attractive assets and creating additional demand.

The IPO window has reopened slightly, but not enough to provide an exit path for every biotech. That means many companies still view acquisition as their most realistic outcome.

In short, capital isn't the scarce resource anymore. Differentiated clinical assets are. And right now, pharma companies seem willing to write very large checks to find them.

That's how many hospitals the Centers for Medicare & Medicaid Services has warned since April for failing to publicly disclose pricing information. The Trump administration says greater transparency can help patients, employers and insurers compare costs before receiving care. Hospitals that fail to comply could face penalties reaching $2 million annually.

Here’s what biotech Redditors are talking about:

🦄 Biotech Companies Accused of Unicorn Hunting
A Reddit discussion about hiring frustrations struck a nerve across biotech. Posters complained that many companies now expect candidates to combine wet lab expertise, bioinformatics, machine learning, regulatory knowledge and business skills into a single role. Several commenters argued firms are posting wish-list job descriptions because the weak hiring market gives them the luxury of waiting for a "perfect" candidate. Others called it simple unicorn hunting disguised as recruiting.

🤖 Is AI Transforming Biotech or Just Generating More PowerPoints?
Biotech Reddit remains divided on AI's real-world impact. While most commenters agreed AI is helping with literature reviews, protein design and workflow efficiency, many rolled their eyes at executives constantly demanding new AI use cases. One commenter summed up the debate perfectly: there's a big difference between AlphaFold and using ChatGPT to write emails. Most agreed the science is real, but the hype cycle is running well ahead of reality.

👁️ Longevity Startup Begins First Human Cellular Reprogramming Trial
Life Biosciences launched an FDA-approved study testing whether aging cells can be rejuvenated, starting with glaucoma patients receiving experimental eye injections.

⚖️ Express Scripts Sues Over Tennessee PBM Law
The pharmacy benefit manager argues Tennessee's FAIR Rx Act is unconstitutional and could disrupt prescription access for patients statewide.

🌳 Startup Raises €2.1M to Grow Wood in Bioreactors
Dutch startup New Dawn Bio says its cultured wood platform can produce timber 10,000 times faster than traditional forestry.

👁️ Ethyreal Bio Launches With $101M to Target Graves Disease and Thyroid Eye Disease
Ethyreal Bio emerged from stealth with $101 million to advance ETHY-001, a monoclonal antibody designed to block the thyroid-stimulating hormone receptor. The company believes targeting TSHR could address both Graves disease and thyroid eye disease through a single mechanism. Unlike current therapies, ETHY-001 is being developed as a long-acting subcutaneous injection that could offer greater convenience for patients. First-in-human studies are expected to begin during the second half of 2026.

🚀 June 18, 1983 – Sally Ride Becomes the First American Woman in Space
On this date, Sally Ride launched aboard Space Shuttle Challenger and became the first American woman to travel into space. While best remembered for breaking barriers, her mission also helped advance space biology and medicine. Ride operated experiments that used microgravity to separate proteins and pharmaceuticals with exceptional purity and helped validate technologies for studying living cells in space. More than four decades later, biotech companies are still building on research first made possible beyond Earth's atmosphere.

Novo may have been hacked this week, but its biggest security advantage might be that nobody can explain a regulatory pathway without a 60-slide deck. Good luck finding a buyer on the dark web willing to sit through a three-hour PowerPoint before purchasing the stolen data.

That’s all for today. See you next week. 👋

📆 Quick reminder: there will be no BioNucleus Briefing on Tuesday, June 23 while we're away on vacation. We’ll be back on Thursday, June 25.

If you’re enjoying BioNucleus, share it with a friend or coworker who’d get value from it. We’re a small operation, and every share makes a bigger difference than you think.

Was this email forwarded to you? Sign up here 👇

Subscribe for free

Follow us on social and stay one step ahead

BioNucleus Briefing lands in the inboxes of 1,100+ scientists, founders, investors, operators, and industry decision-makers twice a week.

If you'd like to sponsor a future issue, just hit reply and let's talk.